Educational comparison — not medical advice. This page compares two compounds for informational purposes. Neither is recommended as treatment. Any protocol decision is a conversation with your licensed healthcare provider.
Home/Peptides/Semaglutide vs Tirzepatide
HEAD-TO-HEAD COMPARISON

Semaglutide vs Tirzepatide

Users researching GLP-class therapy for metabolic or weight-management goals with their provider.

OPTION A
Semaglutide
Semaglutide (Ozempic / Wegovy)
FDA-approved GLP-1 receptor agonist with the largest clinical evidence base for weight and glycemic outcomes.
Full profile →
OPTION B
Tirzepatide
Tirzepatide (Mounjaro / Zepbound)
FDA-approved dual GIP/GLP-1 receptor agonist with superior weight loss efficacy vs semaglutide in head-to-head data.
Full profile →
THE CORE DIFFERENCE

Semaglutide (Ozempic/Wegovy) is a GLP-1 mono-agonist — ~15% mean weight reduction at maintenance dose in STEP trials. Tirzepatide (Mounjaro/Zepbound) adds GIP receptor activity, producing ~22.5% mean weight reduction at maintenance dose in SURMOUNT-1. Head-to-head studies show tirzepatide superior on weight + A1C endpoints. Side-effect profiles are similar (GI-dominant during titration).

FEATURE COMPARISON
Semaglutide
Tirzepatide
Full name
Semaglutide (Ozempic / Wegovy)
Tirzepatide (Mounjaro / Zepbound)
Category
GLP-1
GLP-1
FDA status
FDA-approved as Ozempic (T2D) and Wegovy (chronic weight management).
FDA-approved as Mounjaro (T2D) and Zepbound (chronic weight management).
Half-life
~7 days
~5 days
Typical dosing
0.25 → 2.4 mg weekly (titrated over 16+ weeks)
2.5 → 15 mg weekly (titrated over 20+ weeks)
Route
Subcutaneous (weekly)
Subcutaneous (weekly)
Classification
GLP-1 receptor agonist
Dual GIP + GLP-1 receptor agonist
BIOMARKERS COMMONLY TRACKED
On Semaglutide
  • • HbA1c
  • • Fasting glucose
  • • ApoB
  • • Fasting insulin
  • • LFTs
  • • Weight
On Tirzepatide
  • • HbA1c
  • • Fasting glucose
  • • ApoB
  • • Triglycerides
  • • LFTs
  • • Weight
CALCULATOR
Semaglutide reconstitution →
CALCULATOR
Tirzepatide reconstitution →
CONDITIONS USERS RESEARCH THESE FOR
Informational only — neither compound is presented as a treatment for any condition. These are contexts in which users research these compounds and discuss them with their licensed provider.
METABOLIC
Insulin Resistance
The metabolic pattern where cells become less responsive to insulin — trackable through specific biomarkers before it becomes diabetes.
METABOLIC
Metabolic Syndrome
The constellation of cardiovascular + metabolic risk factors — diagnosed clinically, tracked via a specific marker cluster.
CARDIOVASCULAR
Elevated ApoB (Cardiovascular Risk)
When the atherogenic particle count is elevated — the single most accurate cardiovascular risk lab marker.
METABOLIC
Elevated Visceral Fat
The metabolically-active abdominal fat linked to cardiovascular + insulin-resistance risk. Hard to see; visible in labs.
RELATED COMPARISONS
Tirzepatide vs Retatrutide
Semaglutide vs Retatrutide
Whichever you're tracking, we built the dashboard for it.

Log doses, upload labs, watch the biomarkers trend. StackAI reads your panel in context of what you're actually running.

Start tracking free →

Informational comparison only — not medical advice. Research-stage compounds discussed are not FDA-approved unless specifically noted. Any protocol decision should be made with a licensed healthcare provider.